Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized, double-blind, placebo-controlled study of CE-224,535 in rheumatoid arthritis inadequately controlled with methotrexate
2008-000327-25Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing CE-224,535 + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: ACR20 response at week 12. Started Mar 2008; status: completed.
02
Drugs
CE-224535
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-000327-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000327-25.